Information Provided By:
Fly News Breaks for November 18, 2016
NXTM
Nov 18, 2016 | 06:23 EDT
After hosting investor meetings with management, Piper Jaffray analyst Matt O'Brien says NxStage Medical is still a name to own despite the stock's 20% rally year-to-date. The core HHD business is seeing "significant momentum," O'Brien tells investors in a research note. The analyst believes new capitation programs for dialysis patients could accelerate adoption of HHD. He keeps an Overweight rating on NxStage Medical with a $27 price target.
News For NXTM From the Last 2 Days
There are no results for your query NXTM